首页> 外文期刊>Antimicrobial agents and chemotherapy. >Results from Oritavancin Resistance Surveillance Programs (2011 to 2014): Clarification for Using Vancomycin as a Surrogate To Infer Oritavancin Susceptibility
【24h】

Results from Oritavancin Resistance Surveillance Programs (2011 to 2014): Clarification for Using Vancomycin as a Surrogate To Infer Oritavancin Susceptibility

机译:奥利万星耐药性监测计划(2011年至2014年)的结果:阐明使用万古霉素作为替代品来推断奥利万星易感性

获取原文
获取原文并翻译 | 示例
           

摘要

Measurement of vancomycin susceptibility has been shown to be highly predictive as a surrogate measure of oritavancin susceptibility among clinically indicated Gram-positive species. Results of studying over 30,000 pathogens (from 2011 to 2014) by cross-susceptibility analysis and determining the poor reproducibility of oritavancin-nonsusceptible results showed nearly perfect surrogate testing accuracy (99.86 to 99.94%). Any isolate of an indicated organism species with locally reproducible oritavancin- nonsusceptible results (extremely rare) should be referred to a reference laboratory for confirmation of the results and determination of the resistance mechanism.
机译:万古霉素敏感性的测量已被高度预测,作为临床指示的革兰氏阳性菌种中奥利万星敏感性的替代度量。通过交叉敏感性分析研究了30,000多种病原体(2011年至2014年)并确定了奥利万星非敏感性结果的可重复性差,结果显示替代测试的准确性几乎完美(99.86至99.94%)。任何具有局部可重复生产的奥利万星不敏感结果(极少见)的指定生物物种的分离株,应转交给参考实验室以确认结果并确定耐药机制。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号